3 Top Ways to Trade AI’s Healthcare Revolution

This is just the start... [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here. Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor, Artificial intelligence (AI) is having a mind-blowing impact on society. We’re already seeing its impact with education, finance, military, cybersecurity… you name it. But this is just the start. Big tech is investing billions in AI. In fact, according to CNBC, AI is now the biggest expense for about half of all tech companies. But again, this is just the start. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – could grow twenty-fold by 2030 to more than $2 trillion. All while the technology massively disrupts everything about everything. That includes healthcare and medical technology. For example, according to analysts over at BlackRock, “The greatest surge of new retirees in the nation’s history is fast approaching, and the AI healthcare market, worth $9 billion in 2022, is forecasted to skyrocket to $188 billion in 2031.” Better, “With the implementation of AI in healthcare, it was forecast physicians would be able to spend almost 20 percent more of their time on patients because the time burden of administrative tasks would be reduced,” as noted by Statista. --------------------------------------------------------------- Millionaire Publishing [WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (July 31)]( [video]( This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race… It does NOT involve RFK Jr. or any other 3rd party candidate… And it has NOTHING to do with any kind of government shutdown. But for millions of traders, this could be about to change everything… [Click here to see a unique election-year trade to make now… or risk getting blindsided on July 31st.]( --------------------------------------------------------------- Look at drug discovery, for example. At the moment, it can take 10 to 15 years, and upwards of $2 billion to develop a new drug. Plus, designing new drugs isn’t easy. When creating a new drug, you need to identify a molecule that balances a large number of anti-correlated properties, including potency, selectivity, solubility, bioavailability, clearance/ half-life, permeability, drug interactions, and synthesizability. Even then, drug development has a high failure rate of 90% -- which is ridiculously high. However, with artificial intelligence (AI) the rate of failure could drop, and the design of new drugs could become far easier.  Company: Schrodinger (SYM: SDGR) That being said, investors should keep an eye on stocks such as Schrodinger (SYM: SDGR), which is transforming the way therapeutics and materials are discovered. At the moment, its AI-powered software technology uses physics-based modeling and machine learning (ML) algorithms to help companies identify which molecules can help treat specific ailments. Better, its programs can help predict behavior of molecules and possible outcomes. --------------------------------------------------------------- Daily Strike Alliance [Top upcoming day trade alerts (yours at no cost!)]( There's some insane market activity right now… That's setting up multiple 100%+ intraday trading moves… For the NEXT market open! It's all thanks to a revolutionary trading system, built by 4 pro traders… [Click here to get their TOP upcoming day-trade alerts!]( --------------------------------------------------------------- Companies: Exscientia (SYM: EXAI), Recursion Pharmaceuticals (SYM: RXRX) Or, look at Exscientia (SYM: EXAI), which bills itself as an AI-driven precision medicine company that’s engineering future drugs to help revolutionize drug discovery.  Its patient-first Ai-driven platform allows for a highly efficient and accelerated drug discovery process, which significantly reduces time and costs associated with typical drug discovery methods. All through the use of patient tissue data to “define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting.” There’s also Recursion Pharmaceuticals (SYM: RXRX), a clinical stage TechBio company that’s “decoding” biology to industrialize drug discovery with the help of its Recursion OS. --------------------------------------------------------------- Stock Earnings [Earnings Season: Your FREE Ticket to Trading Success](Don't just survive earnings season - learn how to potentially thrive. Veteran trader reveals strategies for navigating market-moving announcements. Discover how to time your trades for maximum potential profit. Bonus: Daily earnings updates delivered straight to your inbox. [Click here now to claim your free guide before this offer expires!]( --------------------------------------------------------------- [Join Daily Guru Trades!]( Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.]( Do you currently own any AI-healthcare stocks? Do you have your eye on any other under-the-radar AI stocks we might have missed? Hit "reply" to this email and let us know! Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Behind the Markets]( [Unsubscribe](